ShangBay Capital

The firm's website identifies William Dai as Founding Managing Partner and Chaucer Shen as Managing Partner, suggesting they lead investment decisions. A venture partner and a team of senior associates and analysts support execution. However, the partnership does not publicly detail its investment committee structure or individual check-writing authority.

ShangBay's public materials emphasize relationships with key opinion leaders, strategics, and experienced innovators in medical technology. The firm's cadre of clinical and technology senior advisors — including a senior medical advisor — implies a sourcing model that relies on physician networks and industry-insider referrals to identify companies addressing high, unmet clinical needs.

ShangBay Capital is structured as a venture capital firm, not a family office. It raises external capital from investors to deploy into early-stage healthcare companies. Its website describes bringing investors access to investments, indicating a traditional GP-LP venture fund structure rather than a single-family balance sheet.

ShangBay's strategy description centers on direct venture equity participation in early-stage companies, from seed to growth. There is no public indication that it makes fund commitments, invests as a limited partner in other venture funds, or operates a fund-of-funds program.

The firm targets early-stage companies, explicitly listing seed, start-up, expansion, and late-stage growth. It also notes an appetite for complex situations, which may include restructurings or special-situation financings within its narrow healthcare mandate, per Altss research records.

ShangBay Capital does not maintain a public exclude list, but its website exclusively references medical devices, biotechnology, and mobile healthcare. Generalist technology sectors — enterprise software, consumer internet, fintech — are entirely absent from its stated strategy, indicating the firm deliberately avoids non-healthcare verticals.

No philanthropic foundation, donor-advised fund, or impact-investing vehicle is publicly disclosed as affiliated with ShangBay Capital. The firm presents itself solely as a for-profit venture capital manager.